Upadacitinib is a pharmaceutical raw material that functions as a Janus kinase (JAK) inhibitor. It is employed in the manufacturing of medications that modulate inflammatory processes associated with certain autoimmune and inflammatory conditions.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Upadacitinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Upadacitinib hemihydrate
pharmaceutical raw material
Upadacitinib
pharmaceutical raw material
Tipiracil hydrochloride
pharmaceutical raw material
Clindamycin
pharmaceutical raw material
Erlotinib hydrochloride
pharmaceutical raw material
Erlotinib
pharmaceutical raw material
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine dihydrocloride
pharmaceutical intermediate
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine
research compound
(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
WYQFJHHDOKWSHR-MNOVXSKESA-N
CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
Sourcing Upadacitinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.